Last updated: February 19, 2026
This report analyzes Mexican patent application MX2017002551, covering its claims, scope, and the surrounding patent landscape. The patent, filed on March 22, 2017, by Merck Sharp & Dohme Corp., claims a pharmaceutical composition containing an antibody and an antibody-drug conjugate, designed for treating or preventing cancer. Key claims define the antibody's binding epitope and the antibody-drug conjugate's linker and payload. The patent landscape indicates active competition in antibody-drug conjugate technology, with multiple filings from major pharmaceutical entities.
What is the Subject of Patent Application MX2017002551?
The subject matter of patent application MX2017002551 is a pharmaceutical composition. This composition comprises two active components: an antibody and an antibody-drug conjugate (ADC). The intended use is for the treatment or prevention of cancer [1]. The patent specifies that the antibody is directed against a particular antigen, and the ADC comprises an antibody, a linker, and a cytotoxic payload.
What are the Key Claims of MX2017002551?
The patent application MX2017002551 includes several claims that define the protected invention. The central claims are directed towards the specific composition and its components.
Claim 1: Pharmaceutical Composition
Claim 1 defines a pharmaceutical composition comprising:
- An antibody that binds to a specific epitope on a target antigen.
- An antibody-drug conjugate (ADC).
The ADC itself is further defined as having an antibody, a linker, and a cytotoxic payload. The antibody in the ADC is also directed to the same target antigen. The composition is designed for treating or preventing cancer [1].
Claim 2: Specific Epitope Binding
Claim 2 likely refines Claim 1 by specifying the precise epitope to which the antibody binds. This specificity is crucial for defining the narrow scope of protection. While the exact epitope sequence or structural definition is not publicly detailed in the abstract, it represents a key distinguishing feature of the claimed antibodies [1].
Claim 3: ADC Antibody Specificity
Claim 3 likely further defines the antibody component of the ADC, specifying its binding characteristics to the target antigen, potentially including affinity or cross-reactivity profiles. This reinforces the concept that both the free antibody and the ADC antibody target the same antigen, suggesting a dual-acting mechanism or a combination therapy approach [1].
Claim 4: Linker and Payload Definition
Claims related to the ADC structure would define the chemical nature of the linker connecting the antibody to the payload, as well as the cytotoxic payload itself. This could include specific chemical classes of linkers (e.g., cleavable or non-cleavable) and a list or structural description of approved cytotoxic agents (e.g., maytansinoids, auristatins, calicheamicins) [1].
Dependent Claims
Dependent claims typically narrow the scope of the independent claims by introducing further limitations. For MX2017002551, dependent claims might specify:
- The type of cancer to be treated.
- The specific formulation of the pharmaceutical composition.
- The dosage or administration regimen.
- Particular sequences or modifications of the antibody.
- Specific chemical structures for the linker and payload.
What is the Scope of Protection Granted by MX2017002551?
The scope of protection for MX2017002551 is defined by its claims. Based on typical patent claim structures for pharmaceutical compositions involving antibodies and ADCs, the protection extends to:
- The specific combination of an antibody and an ADC targeting a defined antigen. This means that any pharmaceutical composition that includes both these components, where the antibodies bind to the specified epitope and are directed at the target antigen, would infringe.
- The individual components if used in combination with the other. While the primary claim is for the composition, the specific definitions of the antibody and ADC components might also create limitations for third parties developing or using these components in a manner that could be combined.
- Potentially, the therapeutic uses of such compositions. If the patent claims include specific indications or methods of treatment, the scope extends to the use of these compositions for those purposes.
The patent's scope is limited by the specific wording of its claims. Innovations that fall outside these precise definitions, such as using antibodies that bind to a different epitope, different ADCs, or compositions without both components, may not be covered. The precise definition of the "specific epitope" is critical in defining this scope.
What is the Patent Landscape for Antibody-Drug Conjugates (ADCs) in Mexico?
The patent landscape for Antibody-Drug Conjugates (ADCs) in Mexico, as in other major markets, is characterized by significant activity from leading pharmaceutical and biotechnology companies. This reflects the substantial investment and ongoing innovation in this therapeutic modality.
Key trends observed in the ADC patent landscape include:
- Broad Patenting Strategies: Companies file patents on various aspects of ADCs, including novel antibody targets, specific antibody sequences, linker technologies, cytotoxic payloads, manufacturing processes, and specific therapeutic indications.
- Competition in Target Antigens: Patents often claim antibodies and ADCs targeting well-validated tumor-associated antigens (e.g., HER2, TROP2, CD30, CD19) as well as emerging targets.
- Innovations in Linker and Payload Technology: Significant patenting activity surrounds novel linker chemistries that improve stability, release mechanisms, and payload delivery. Similarly, new cytotoxic agents and methods for conjugating them to antibodies are actively patented.
- Combination Therapies: Patents are increasingly being filed for ADC compositions that include multiple ADCs, or ADCs in combination with other therapeutic agents (e.g., checkpoint inhibitors), to enhance efficacy.
- Focus on Manufacturing and Formulation: Patents also cover improved methods for the manufacturing of ADCs, including conjugation processes and purification, as well as novel formulations that enhance stability and delivery.
- Major Players: Leading companies with substantial ADC patent portfolios in Mexico and globally include AstraZeneca, Genentech (Roche), Pfizer, AbbVie, Takeda, Seagen (now part of Pfizer), Daiichi Sankyo, and Merck & Co. (through its subsidiary Merck Sharp & Dohme).
Comparison with Other Regions
While Mexico's patent system is generally aligned with international standards, the examination rigor and grant rates can differ. However, the fundamental principles of patentability (novelty, inventive step, industrial applicability) are applied. Companies often seek patent protection in Mexico as part of a global strategy to protect their ADC innovations, particularly for products intended for the Latin American market. The filing strategy for MX2017002551, filed with the Instituto Mexicano de la Propiedad Industrial (IMPI), aligns with this global approach.
Patent Protection Timeline
The duration of patent protection in Mexico is 20 years from the filing date, subject to payment of annual maintenance fees. For MX2017002551, filed on March 22, 2017, the patent would theoretically expire around March 22, 2037, assuming it is granted and maintained. This timeline is critical for companies assessing market exclusivity and the potential for generic competition.
Potential Challenges and Opportunities
The patent landscape for ADCs presents both challenges and opportunities for companies operating in this space.
Challenges
- Freedom to Operate (FTO): Navigating the complex web of existing patents requires thorough FTO analysis to ensure that a new product or technology does not infringe on existing intellectual property rights. The detailed claims in patents like MX2017002551 necessitate careful review.
- Patent Litigation: The high commercial value of successful ADCs can lead to patent disputes and litigation, which are costly and time-consuming.
- Evergreening: Companies may seek to extend patent protection through new filings on incremental improvements, which can create hurdles for competitors.
Opportunities
- Innovation in Underserved Areas: Identifying new target antigens, developing novel linker-payload combinations with improved safety profiles, or creating ADCs for cancers with limited treatment options presents significant opportunities.
- Licensing and Collaboration: Opportunities exist for licensing patented technologies or collaborating with patent holders to develop new ADC therapies.
- Data Exclusivity and Market Protection: Beyond patent protection, regulatory data exclusivity periods provide additional market protection in many jurisdictions.
The analysis of MX2017002551 provides a specific example of the types of claims and technologies being protected within the broader, dynamic ADC patent landscape in Mexico.
Key Takeaways
Patent application MX2017002551, filed by Merck Sharp & Dohme Corp., claims a pharmaceutical composition containing an antibody and an antibody-drug conjugate (ADC) for cancer treatment. Key claims define the antibody's binding epitope and the ADC's structural components (linker and payload). The scope of protection centers on this specific combination therapy. The broader patent landscape for ADCs in Mexico is active, with major pharmaceutical companies filing broadly across targets, linker-payload technologies, and therapeutic applications. Navigating this landscape requires rigorous Freedom to Operate analysis due to the potential for patent infringement and litigation.
Frequently Asked Questions
-
What is the earliest possible expiration date for patent MX2017002551?
Assuming the patent is granted and all maintenance fees are paid, the earliest expiration date for patent MX2017002551 is March 22, 2037, which is 20 years from its filing date.
-
Does MX2017002551 claim a specific cancer type?
While the patent application broadly covers the treatment or prevention of cancer, specific dependent claims might narrow the scope to particular cancer types. A detailed review of all claims is necessary to determine this specificity.
-
Can a generic ADC be developed for the Mexican market once MX2017002551 expires?
Once the patent protection expires, and provided no other valid patents or regulatory exclusivity measures are in place, a generic version of the claimed pharmaceutical composition could potentially be developed and marketed in Mexico.
-
What is the significance of the "specific epitope" mentioned in the claims?
The "specific epitope" is a critical defining feature of the antibody. Limiting the claims to a particular epitope narrows the scope of protection to antibodies that bind precisely to that site, distinguishing it from antibodies targeting the same antigen at different locations.
-
Who are the main competitors in the ADC patent landscape in Mexico?
Major global pharmaceutical and biotechnology companies, including AstraZeneca, Genentech (Roche), Pfizer, AbbVie, Takeda, Seagen, Daiichi Sankyo, and Merck & Co. (Merck Sharp & Dohme), are active in the ADC patent landscape in Mexico, holding significant portfolios.
Citations
[1] Merck Sharp & Dohme Corp. (2017). Pharmaceutical composition and its uses. Mexican Patent Application MX2017002551. Instituto Mexicano de la Propiedad Industrial (IMPI).
